Cases
Spectrum Pharmaceuticals, Inc. (NASDAQ : SPPI)
Securities Class Action
Overview
Overview
- Date:
- 9/29/2016
- Company Name:
- Spectrum Pharmaceuticals, Inc.
- Stock Symbol:
- SPPI
- Class Period:
- FROM 2/28/2013 TO 9/16/2016
- Status:
- Closed/Complete
- Court:
- U.S. District Court: Central California
NEW YORK, September 29, 2016 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the California Central District Court on behalf of all persons or entities who acquired Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) securities between February 28, 2013 to September 16, 2016 (the “Class Period”).
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA previously questioned whether the data from the 611 and 612 Studies were clinically meaningful; (2) the FDA advised defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) as a result, defendants’ public statements about Spectrum’s business, operations and prospects were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damage.
If you acquired Spectrum securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the FDA previously questioned whether the data from the 611 and 612 Studies were clinically meaningful; (2) the FDA advised defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) as a result, defendants’ public statements about Spectrum’s business, operations and prospects were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damage.
If you acquired Spectrum securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.